403 results on '"Carrascosa, JM"'
Search Results
2. Recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave
3. Actualización en el posicionamiento del Grupo Español de Psoriasis (GPS) en la utilización de medicamentos biosimilares en psoriasis moderada-grave
4. BIOBADATOP: Registro Español de Dermatitis Atópica. Descripción y primeros resultados
5. [Translated article] Implementation of Recommendations for the Management of Psoriasis During Preconception, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care
6. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
7. HTA3 The Clinical and Economic Value of a Sustained Response in the Treatment of Moderate-to-Severe Psoriasis in Spain: The PSOVALUE Project
8. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
9. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
10. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
11. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
12. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey
13. A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?
14. Patient Journey in Atopic Dermatitis: The Real-World Scenario
15. Lymphocyte subpopulations analysis in psoriatic patients treated with biological drugs
16. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
17. Baricitinib for the treatment of atopic dermatitis
18. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
19. Spotlight on Topical Long-Term Management of Plaque Psoriasis
20. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
21. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
22. Prospective observational study to evaluate the benefits for the patient associated with the treatment of plaque psoriasis with apremilast after other systemic treatments in conditions of clinical practice in Spain (APPROPRIATE study)
23. Treatment Appraisal Reports: Usefulness and Transparency
24. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
25. Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
26. The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis
27. Apremilast for psoriasis treatment
28. Summary of efficacy, impact on work productivity and activity, and safety of baricitinib in moderate-to-severe atopic dermatitis from two monotherapy phase III trials
29. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
30. Generalized cutaneous drug eruption due to strontium ranelate
31. The Use of Apremilast in Psoriasis: A Delphi Study
32. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
33. Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis (vol 89, pg 301, 2018)
34. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
35. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
36. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
37. ECONOMIC IMPACT OF ATOPIC DERMATITIS IN ADULTS: A POPULATION STUDY (IDEA STUDY)
38. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
39. Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy
40. Absolute and relative psoriasis area and severity indices over 1 year of treatment with ixekizumab: A descriptive analysis in patients with moderate-to-severe plaque psoriasis
41. Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
42. Economic Impact Of Atopic Dermatitis In Adults: A Population Study (Idea Study)
43. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice
44. Perfil epidemiológico, clínico, y alérgico en pacientes con psoriasis. Evaluación del Registro Español de Dermatitis de Contacto (REIDAC)
45. Fototerapia, una alternativa para el manejo de la forma crónica de enfermedad del injerto contra huésped (EICH)
46. Budget Impact Analysis of Apremilast on Moderate to Severe Psoriasis In Spain
47. Cost-Utility Analysis of Apremilast for The Treatment of Moderate to Severe Psoriasis In Spain
48. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate:a randomized clinical trial (TRANSIT)
49. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis
50. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.